Search

Displaying results 1491 - 1500 of 7889 in total
  1. Drug

    gamma-Hydroxybutyric acid

    go.drugbank.com/drugs/DB01440
    ApprovedIllicitInvestigational

    It is used illegally under the street names Juice, Liquid Ecstasy or simply G, either as an intoxicant, or as a date rape drug. … Today Xyrem is a Schedule III drug; however GHB remains a Schedule I drug and the illicit use of Xyrem falls under penalties of Schedule I.

  2. Drug

    Urethane

    go.drugbank.com/drugs/DB04827
    ApprovedWithdrawn

    Urethane, formerly marketed as an inactive ingredient in Profenil injection, was determined to be carcinogenic and was removed from the Canadian, US, and UK markets in 1963.

  3. Drug

    Ferrous asparto glycinate

    go.drugbank.com/drugs/DB11169
    Approved

    Ferrous asparto glycinate is an iron-amino acid chelate. It is available as a dietary supplement used in the treatment of iron deficiency and iron deficiency anemia.

    Mixtures: Paire OB Plus DHA, OB Complete DHA
  4. Drug

    Technetium Tc-99m oxidronate

    go.drugbank.com/drugs/DB09139
    ApprovedWithdrawn

    [L1139] Thus, technetium Tc-99m oxidronate is a powerful detection tool for abnormal osteogenesis by skeletal scintigraphy. … A radiopharmaceutical is defined as a medicinal formulation containing radioisotopes that are used in major clinical areas for diagnosis and/or therapy.

  5. Drug

    Hexafluronium

    go.drugbank.com/drugs/DB00941
    Approved

    Hexafluronium bromide is a neuromuscular blocking agent used in anesthesiology to prolong and potentiate the skeletal muscle relaxing action of suxamethonium during surgery.

  6. Drug

    Thrombin alfa

    go.drugbank.com/drugs/DB11572
    Approved

    Thrombin Alfa precursor is secreted to culture medium as single chain form that is proteolytically converted to a two-chain active form (using a protein derived from snakes) and is purified by a chromatographic … Thrombin Alfa is a human coagulation protein produced via recombinant DNA technology from a genetically modified CHO cell line.

  7. Drug

    Baxdrostat

    go.drugbank.com/drugs/DB19090
    ApprovedInvestigational

    On May 18, 2026, baxdrostat was approved by the FDA as a first-in-class aldosterone synthase inhibitor for the treatment of hypertension in combination with other antihypertensive drugs [L56189]. … Baxdrostat offers an upstream alternative to traditional mineralocorticoid receptor antagonists (MRAs), such as [spironolactone], which often induce off-target endocrine side effects like gynecomastia

  8. Drug

    Taletrectinib

    go.drugbank.com/drugs/DB18711
    ApprovedInvestigational

    [L53308] Gene fusions involving _ROS1_, a proto-oncogene, have been identified as oncogenic drivers in 1-2% of patients with non-small cell lung cancer (NSCLC), in addition to other cancers at variable … Taletrectinib is an orally available small molecule kinase inhibitor.

  9. Drug

    Lorlatinib

    go.drugbank.com/drugs/DB12130
    ApprovedInvestigational

    include lorlatinib as a first-line treatment option in advanced ALK-positive NSCLC. … Lorlatinib is a third-generation ALK tyrosine kinase inhibitor (TKI) for patients with ALK-positive metastatic non-small cell lung cancer[L39905] which was first approved by the US FDA in November of 2018

  10. Drug

    Chlorcyclizine

    go.drugbank.com/drugs/DB08936
    Approved

    Chlorcyclizine also has some local anesthetic, anticholinergic, and antiserotonergic properties, and can be used as an antiemetic. … Chlorcyclizine is a first generation phenylpiperazine class antihistamine used to treat urticaria, rhinitis, pruritus, and other allergy symptoms.

    Mixtures: Stahist Ad, Stahist AD